Veru (VERU) shares were up more than 8% in Tuesday's premarket activity after the company disclosed the sale of its FC2 female condom business to clients managed by Riva Ridge Capital Management and co-investors for around $18 million.
The sale, as well as the transfer of Veru's UK and Malaysian units, reduces the company's headcount to 22 from 210 and is expected to generate about $12.5 million after royalty payments and other adjustments.
The sale of the internal condom business "allows Veru to be a pure biopharmaceutical company," said Mitchell Steiner, chairman, president, and chief executive of Veru.
The company also said it is expecting clinical results in January from a phase 2b clinical trial of its drug enobosarm as a potential treatment to preserve muscle in patients with sarcopenic obesity or overweight elderly patients who are taking semaglutide.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.